National Marketing Authorisation for Metvix® PDT issued in Finland
Oslo, May 23rd 2002.
PhotoCure ASA announces today that the company has received national marketing authorisation for Metvix® PDT (Photodynamic Therapy) in Finland. As national marketing authorisations have already been granted in Sweden, Norway, Iceland and Denmark, the Finnish authorisation means that PhotoCure now has received marketing authorisations for all the Nordic countries.
Product specialists are currently marketing Metvix® PDT in Sweden, while pre-launch activities are ongoing in Norway, Denmark and Finland. In addition to arranging national conferences, these activities include price and reimbursement applications, and educational programs in the use of Metvix® PDT. PhotoCure does not expect significant sales before these activities are completed.
PhotoCure has licensed the rights to marketing and sale of Metvix® PDT to Galderma S.A. outside the Nordic area, but has retained these rights in the Nordic countries.
As of today, Metvix® PDT is approved in 14 European countries and New Zealand and applications are pending in other countries including the US.
Product specialists are currently marketing Metvix® PDT in Sweden, while pre-launch activities are ongoing in Norway, Denmark and Finland. In addition to arranging national conferences, these activities include price and reimbursement applications, and educational programs in the use of Metvix® PDT. PhotoCure does not expect significant sales before these activities are completed.
PhotoCure has licensed the rights to marketing and sale of Metvix® PDT to Galderma S.A. outside the Nordic area, but has retained these rights in the Nordic countries.
As of today, Metvix® PDT is approved in 14 European countries and New Zealand and applications are pending in other countries including the US.